Sakineh Mohammadian1, Nasrin Fatahi2, Hossein Zaeri3, Mohammad Ali Vakili3. 1. Associate Professor, Neonatal and Children Health Reasearch Centre, Golestan University of Medical Science, Neonatal and Children Health Research Center , Gorgan, Iran . 2. Pediatric Resident, Neonatal and Children Health Reasearch Centre, Golestan University of Medical Science, Neonatal and Children Health Research Center , Gorgan, Iran . 3. Assistant Professor, Neonatal and Children Health Reasearch Centre, Golestan University of Medical Science, Neonatal and Children Health Research Center , Gorgan, Iran .
Abstract
BACKGROUND: Glycemic control prevents microvascular complications in patients with type I diabetes mellitus such as retinopathy, nephropathy and neuropathy that influences quality of life. Some studies show the immunomodulatory effect of vitamin D in synthesis and secretion of insulin. AIMS: In this study we evaluate glycemic changes after vitamin D3 supplement in children with type I diabetes mellitus and vitamin D deficiency. MATERIALS AND METHODS: In children with type I diabetes mellitus, level of vitamin D and HbA1C was measured. Patients with type I diabetes mellitus who had vitamin D deficiency (25OHD < 50 nmol/lit) treated with 300,000 units of vitamin D3. Calcium supplement (40mg/kg/day) divided in two doses in order to avoid hungry bone was also used. After three months, 25OHD and HbA1C were measured again. Differences, in mean ± SD HbA1C and 25OHD were evaluated before and after the study. RESULTS: Mean ± SD HbA1C was 9.73±1.85 before the study which was diminished to 8.55±1.91 after vitamin D3 supplement treatment. This decline has a significant difference (p-value < 0.0001). Mean ± SD 25OHD was 17.33±8.97 nmol/lit before the study which is increased to 39.31±14.38 nmol/lit after treatment with vitamin D3 supplement. This increase also has a significant difference (p-value < 0.0001). Vitamin D3 supplement causes the improvement of HbA1C in all groups of glycemic control including HbA1C <7.8, 7.8-9.9, and >9.9. This supplement transfer patients toward better glycemic control for the entire group (p-value < 0.0001). CONCLUSION: Vitamin D3 supplement improves HbA1C in pediatrics with type I diabetes mellitus and vitamin D deficiency.
BACKGROUND: Glycemic control prevents microvascular complications in patients with type I diabetes mellitus such as retinopathy, nephropathy and neuropathy that influences quality of life. Some studies show the immunomodulatory effect of vitamin D in synthesis and secretion of insulin. AIMS: In this study we evaluate glycemic changes after vitamin D3 supplement in children with type I diabetes mellitus and vitamin D deficiency. MATERIALS AND METHODS: In children with type I diabetes mellitus, level of vitamin D and HbA1C was measured. Patients with type I diabetes mellitus who had vitamin D deficiency (25OHD < 50 nmol/lit) treated with 300,000 units of vitamin D3. Calcium supplement (40mg/kg/day) divided in two doses in order to avoid hungry bone was also used. After three months, 25OHD and HbA1C were measured again. Differences, in mean ± SD HbA1C and 25OHD were evaluated before and after the study. RESULTS: Mean ± SD HbA1C was 9.73±1.85 before the study which was diminished to 8.55±1.91 after vitamin D3 supplement treatment. This decline has a significant difference (p-value < 0.0001). Mean ± SD 25OHD was 17.33±8.97 nmol/lit before the study which is increased to 39.31±14.38 nmol/lit after treatment with vitamin D3 supplement. This increase also has a significant difference (p-value < 0.0001). Vitamin D3 supplement causes the improvement of HbA1C in all groups of glycemic control including HbA1C <7.8, 7.8-9.9, and >9.9. This supplement transfer patients toward better glycemic control for the entire group (p-value < 0.0001). CONCLUSION:Vitamin D3 supplement improves HbA1C in pediatrics with type I diabetes mellitus and vitamin D deficiency.
Authors: P D Robinson; W Högler; M E Craig; C F Verge; J L Walker; A C Piper; H J Woodhead; C T Cowell; G R Ambler Journal: Arch Dis Child Date: 2005-06-14 Impact factor: 3.791
Authors: Harleen Kaur; Kim C Donaghue; Albert K Chan; Paul Benitez-Aguirre; Stephen Hing; Margaret Lloyd; Janine Cusumano; Alison Pryke; Maria E Craig Journal: Diabetes Care Date: 2011-04-22 Impact factor: 19.112
Authors: Thais C Maia-Ceciliano; Andre R C Barreto-Vianna; Sandra Barbosa-da-Silva; Marcia B Aguila; Tatiane S Faria; Carlos A Mandarim-de-Lacerda Journal: Endocrine Date: 2016-05-03 Impact factor: 3.633
Authors: R Perchard; L Magee; A Whatmore; F Ivison; P Murray; A Stevens; M Z Mughal; S Ehtisham; J Campbell; S Ainsworth; M Marshall; M Bone; I Doughty; P E Clayton Journal: Endocr Connect Date: 2017-04-05 Impact factor: 3.335
Authors: Ahmed El-Abd Ahmed; Hala M Sakhr; Mohammed H Hassan; Mostafa I El-Amir; Hesham H Ameen Journal: Diabetes Metab Syndr Obes Date: 2019-05-14 Impact factor: 3.168